The hypothesis is that the implementation of an initial Pharmaceutical Consultation (PC) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could optimize their compliance with the delivered per os treatment.

The aim of this study is therefore to develop a standardised reference guide of information to be provided during prostate cancer in order to optimise the compliance of patients treated for multiple myeloma as a first course of chemotherapy per os.

Inclusion criteria

• The patient must be a member or beneficiary of a health insurance plan
• The patient is at least 18 years old
• The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.

Criteria for non-inclusion

• The subject is participating in another study
• The subject is in an exclusion period determined by a previous study
• The subject is under the protection of justice, guardianship or curatorship
• It is impossible to give informed information about
• The patient is pregnant, parturient, or breastfeeding
• The patient receives a follow-up by a home nurse for the administration of oral medication
• The patient is treated only with oral chemotherapy in the city
• The patient has early dementia.

Translated with www.DeepL.com/Translator

-

The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.